Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 2, pp 303–309 | Cite as

Free phenytoin assessment in patients: measured versus calculated blood serum levels

  • Andrea Tobler
  • Raphael Hösli
  • Stefan MühlebachEmail author
  • Andreas Huber
Research Article

Abstract

Background Total serum drug levels are routinely determined for the therapeutic drug monitoring of selected, difficult-to-dose drugs. For some of these drugs, however, knowledge of the free fraction is necessary to adapt correct dosing. Phenytoin, with its non-linear pharmacokinetics, >90 % albumin binding and slow elimination rate, is such a drug requiring individualization in patients, especially if rapid intravenous loading and subsequent dose adaptation is needed. In a prior long-term investigation, we showed the excellent performance of pharmacy-assisted Bayesian forecasting support for optimal dosing in hospitalized patients treated with phenytoin. In a subgroup analysis, we evaluated the suitability of the Sheiner-Tozer algorithm to calculate the free phenytoin fraction in hypoalbuminemic patients. Objective To test the usefulness of the Sheiner-Tozer algorithm for the correct estimation of the free phenytoin concentrations in hospitalized patients. Setting A Swiss tertiary care hospital. Method Free phenytoin plasma concentration was calculated from total phenytoin concentration in hypoalbuminemic patients and compared with the measured free phenytoin. The patients were separated into a low (35 ≤ albumin ≥ 25 g/L) and a very low group (albumin <25 g/L) for comparing and statistically analyzing the calculated and the measured free phenytoin concentration. Main outcome measures Calculated and the measured free phenytoin concentration. Results The calculated (1.2 mg/L (SD = 0.7) and the measured (1.1 mg/L (SD = 0.5) free phenytoin concentration correlated. The mean difference in the low and the very low albumin group was: 0.10 mg/L (SD = 1.4) (n = 11) and 0.13 mg/L (SD = 0.24) (n = 12), respectively. Although the variability of the data could be a bias, no statistically significant difference between the groups was found: t test (p = 0.78), the Passing–Bablok regression, the Spearman’s rank correlation coefficient of r = 0.907 and p = 0.00. The Bland–Altman plot including the regression analysis revealed no systematic differences between the calculated and the measured value [M = 0.11 (SD = 0.28)]. Conclusion In absence of a free phenytoin plasma concentration measurement also in hypoalbuminemic patients, the Sheiner-Tozer algorithm represents a useful tool to assist therapeutic monitoring to calculate or control free phenytoin by using total phenytoin and the albumin concentration.

Keywords

Phenytoin Serum concentrations Sheiner-Tozer equation Therapeutic Drug Monitoring (TDM) 

Notes

Acknowledgements

The authors would especially like to thank Erica Holt and Bettina Nyffengger, University of Bern, for their helpful advice and support.

Funding

The investigation was supported by the Kantonsspital Aarau (Switzerland); (Fund for Science and Continuing Education) and the University of Basel (third-party Grant FO119900 for Clinical Pharmacy, and related scientific projects).

Conflicts of interest

The authors declare no conflicts of interest. The submitting author is scientific director at Vifor Pharma Ltd. The company has not been involved in this investigation and did not influence any aspect of the study.

References

  1. 1.
    Bullock MR, Povlishock JT. Guidelines for the management of severe traumatic brain injury. Editor’s Commentary. J Neurotrauma. 2007;24 Suppl 1:2 p (preceding S1. Erratum in: J Neurotrauma. 2008;25(3):276–8).Google Scholar
  2. 2.
    Evans WE, Oellerich M, Holt DW. Drug monitoring, Leitfaden für die klinische Praxis. 2nd ed. Wiesbaden: Abbott; 1994.Google Scholar
  3. 3.
  4. 4.
    Adam D, Büch HP, Büch U, Christ W, Coper H, Dörfler H, et al. Allgemeine und Spezielle Pharmakologie und Toxikologie. 5th ed. Mannheim: Wissenschaftsverlag; 1987.Google Scholar
  5. 5.
    Schaefer U, Höchner P, Karrer C. Arzneimittel-Kompendium der Schweiz. 32nd ed. Basel: Documed AG; 2011.Google Scholar
  6. 6.
    Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977;5(6):579–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol. 2009;65(2):109–19.CrossRefPubMedGoogle Scholar
  8. 8.
    Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med. 2002;40(10):986–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med. 1999;123(9):822–3.PubMedGoogle Scholar
  10. 10.
    Kumps AH. Therapeutic drug monitoring: a comprehensive and critical review of analytical methods for anticonvulsive drugs. J Neurol. 1982;228(1):1–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99(2):133–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Zielmann S, Mielck F, Kahl R, Kazmaier S, Sydow M, Kolk J, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit. 1994;16(2):139–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Johansen K, Krogh M, Andresen AT, Christophersen AS, Lehne G, Rasmussen KE. Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;669(2):281–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit. 1996;18(1):97–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Tobler A, Mühlebach S. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013;35(5):790–7.CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles in therapeutics. New York: Macmillan; 1978. p. 71–109.Google Scholar
  18. 18.
    Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem. 1983;21(11):709–20.PubMedGoogle Scholar
  19. 19.
    Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother. 1995;29(7–8):667–70.PubMedGoogle Scholar
  20. 20.
    Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J. 2009;50(4):517–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7(5):434–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Krasowski MD, Penrod LE. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak. 2012;14(12):7.CrossRefGoogle Scholar
  23. 23.
    von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28(11):1391–400.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2016

Authors and Affiliations

  • Andrea Tobler
    • 1
  • Raphael Hösli
    • 1
  • Stefan Mühlebach
    • 1
    Email author
  • Andreas Huber
    • 2
  1. 1.Division of Clinical Pharmacy and Epidemiology and Hospital PharmacyUniversity of BaselBaselSwitzerland
  2. 2.Kantonsspital AarauAarauSwitzerland

Personalised recommendations